2024
Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy
Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.Peer-Reviewed Original ResearchProstate biopsyRisk factorsEffective pain management strategiesDiagnosed prostate cancerPain management strategiesIn-office proceduresModern management optionsNonadherence to treatmentContemporary management optionsEnhance patient comfortInnovative imaging modalitiesExperience of painFusion biopsyProstate volumePain intensityProstate cancerPain varyPatient ageIncreased painFollow-upIn-officeManagement optionsSurveillance adherenceBiopsyPharmacological analgesics
2023
Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy
Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.Peer-Reviewed Original ResearchConceptsMagnetic resonance imaging-ultrasound fusionMRF-TBLow-risk diseaseSystematic biopsyLower riskRisk groupingProstate biopsyActive surveillanceHigh riskProstate cancer risk stratificationIntermediate-risk criteriaIntermediate-risk diseaseSystematic prostate biopsyCancer risk stratificationPrimary study objectiveNCCN guidelinesImage-guided approachLocalized cancerRisk stratificationBenign findingsProstate cancerClinical riskDiagnostic yieldRetrospective analysisBiopsy
2022
Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.
Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.Peer-Reviewed Original ResearchConceptsGrade group 2Prostate biopsyRadical prostatectomyAdverse outcomesGroup 2GG-2Core prostate biopsyProstate cancer outcomesPatient's clinical riskClinical risk assessmentCore needle biopsyOngoing clinical needAdverse outcome predictionRetrospective reviewAdverse pathologyCAPRA scoreEntire cohortCancer outcomesPathologic diagnosisNeedle biopsyClinical riskDisease outcomeProstate cancerBiopsyDisease onePD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES
Khajir G, Press B, Sprenkle P, Washington S, Cooperberg M, Leapman M. PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES. Journal Of Urology 2022, 207: e690. DOI: 10.1097/ju.0000000000002602.04.Peer-Reviewed Original ResearchDistribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.
Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.Peer-Reviewed Original ResearchMRI-ultrasound fusion biopsyNCCN risk classificationMRI-ultrasound fusionFusion biopsyLower riskActive surveillanceNCCN riskSystematic biopsyCore biopsyRisk classificationFirst-time biopsyInitial active surveillanceProportion of patientsMajority of patientsEra of MRIPrimary study objectiveProstate cancer risk classificationNCCN definitionsMedian PSASurveillance biopsiesBiopsy cohortRetrospective studySingle institutionProstate cancerBiopsy
2018
MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE
Hsiang W, Ghabili K, Lu A, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE. Journal Of Urology 2018, 199: e209. DOI: 10.1016/j.juro.2018.02.567.Peer-Reviewed Original ResearchRole of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions.
Lu A, Ghabili K, Nguyen K, Sprenkle P. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyProstate lesionsSignificant cancerProstate cancerSignificant cancer detection rateMRI-US fusion biopsyHigher PIRADS scoresHigh Gleason scoreSignificant prostate cancerMRI-ultrasound fusion biopsyProstate Imaging ReportingClinical suspicionGleason scorePIRADS scoreBiopsy histologyTemplate biopsyDetection rateLesion volumePathology gradeBiopsy coresMultiparametric MRILesion basisBiopsyImaging ReportingHow many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy?
Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyMulti-parametric MRILesion basisMRI-US fusion biopsyHistory of PCaHigh-grade cancerSignificant prostate cancerMRI-ultrasound fusion biopsyMpMRI studiesClinical suspicionPrimary outcomeSignificant PCaLesion biopsyDetection rateProstate cancerBiopsy coresBiopsyRegion of interestLesion targetingGenitourinary radiologistsCancerLesionsPatientsOne-quarterIs PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?
Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.Peer-Reviewed Original ResearchSmaller prostate volumeMulti-parametric MRISignificant prostate cancerProstate volumeProstate cancerROI ratioPSA densityGrade groupPrediction of csPCaRisk of csPCaData System (BI-RADS) category 3Prostate Imaging ReportingMpMRI findingsBiopsy databasePrior diagnosisTargeted biopsiesFusion biopsyPositive coresCsPCaUnnecessary biopsiesBiopsyMultivariate analysisPatientsImaging ReportingLesions
2016
MRI-US fusion targeted biopsy results in patients without history of prostate biopsy.
Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.Peer-Reviewed Original ResearchBiopsy-naive menMRI-US fusionGleason scoreProstate cancerMapping biopsyProstate biopsyCS prostate cancerPre-biopsy mpMRITemplate mapping biopsyLow-grade diseaseCancer detection rateMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreCS cancerPrevious biopsyPrior biopsyBiopsy resultsFusion biopsyInclusion criteriaMp-MRIPatient basisPatientsBiopsyCancer
2015
MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALE
Kardos S, Pan S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALE. Journal Of Urology 2015, 193: e179. DOI: 10.1016/j.juro.2015.02.850.Peer-Reviewed Original Research